The Technical Analyst
Select Language :
Rapt Therapeutics Inc [RAPT]

Exchange: NasdaqGM Sector: Healthcare Industry: Biotechnology

Rapt Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Rapt Therapeutics Inc is listed at the NASDAQ Exchange

-0.99% $18.07

Last updated: 3 jul 2022 - 20:47

TimeZone: America/New_York


FUNDAMENTALS
MarketCap: 535.72 mill
EPS: -2.56
P/E: 0.000
Earnings Date: Aug 09, 2022
SharesOutstanding: 29.65 mill
Avg Daily Volume: 0.373 mill
RATING 2022-07-01
B
Neutral
RATINGDETAILS
Rating CashFlow: Strong Buy
Return On Equity: Sell
Return On Asset: Sell
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
4/201/212/213/214/211/22
Revenue
Gr.Profitn/an/an/an/a
Ebit
Asset
Debtn/an/an/an/an/an/a
DISCOUNTED CASH FLOW VALUE
$18.95
(4.85%) $0.877
Date: 2022-07-04
True Range Average
+/- $1.422
( +/- 7.87%)
Range: 16.65 - 19.49
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-05-25 Column Group Ii, Lp Buy 63 Common Stock
2022-05-25 Column Group Ii, Lp Buy 1 837 Common Stock
2022-05-25 Robbins Wendye Buy 8 500 Stock Option (right to buy)
2022-05-25 Rieflin William Jl Buy 8 500 Stock Option (right to buy)
2022-05-25 Lyons-williams Lori Buy 8 500 Stock Option (right to buy)
INSIDER POWER
77.82
Last 100 transactions
Buy: 1 891 233 | Sell: 253 079

Forecast: 16:00 - $18.07

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $18.07
Forecast 2: 16:00 - $18.07
Forecast 3: 16:00 - $18.07
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $18.07 (-0.99% )
Volume 0.132 mill
Avg. Vol. 0.373 mill
% of Avg. Vol 35.42 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Rapt Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Rapt Therapeutics Inc

RSI

Intraday RSI14 chart for Rapt Therapeutics Inc

Last 10 Buy & Sell Signals For RAPT

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since 31-12-69

Date Signal @ Closed %
Jun 28 - 16:58buy$18.02N/AActive
The Live Chart for Rapt Therapeutics Inc
Profile picture for
            Rapt Therapeutics Inc

RAPT

Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 64 full-time employees. The company is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. The company has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.

Last 10 Buy Signals
Date Signal @
NXSUSDJul 3 - 20:450.137
ARKUSDJul 3 - 20:420.423
UBQUSDJul 3 - 20:410.0336
BLOCKUSDJul 3 - 20:390.182
PARTUSDJul 3 - 20:390.328
BLOCKUSDJul 3 - 20:350.183
XLMUSDJul 3 - 20:350.109
MTLUSDJul 3 - 20:351.268
PARTUSDJul 3 - 20:340.328
SNMUSDJul 3 - 20:340.0570

Stock Peers

Company Price Change
RAPT18.07-0.99%
ACET14.680.55%
ALBO21.136.39%
CNTA5.176.16%
IRMD33.51-1.27%
KNTE12.751.11%
LFLY4.26-5.33%
NUVL13.55-0.07%
PRAX2.512.45%
RLYB7.54-0.13%
VXRT3.757.14%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.